Opinion
Video
Early Detection to Expert Dosing: The Pharmacist’s Clinical Role in TD Management
Panelists discuss how pharmacists, through frequent patient contact and vigilant observation, are uniquely positioned to identify early signs of tardive dyskinesia, conduct AIMS assessments, monitor treatment efficacy, foster patient trust, and provide crucial education to support timely intervention and improve long-term management outcomes.
Pharmacists are uniquely positioned to identify early signs of tardive dyskinesia (TD) because they often see patients more frequently than other health care providers, especially in outpatient settings. This regular contact allows them to notice subtle changes in movements that might indicate TD, such as unusual perioral motions or other involuntary movements. Observing behaviors like chewing gum to mask symptoms can be a clue. When something suspicious arises, pharmacists can perform a formal Abnormal Involuntary Movement Scale (AIMS) assessment and communicate findings with the patient’s health care team. Documentation and consistent follow-up are essential, using pharmacy systems or spreadsheets to track symptom progression and treatment responses over time. This vigilance helps catch potential issues early and supports timely intervention, including medication adjustments or referrals.
Monitoring treatment efficacy for TD involves ongoing observation and patient engagement. Pharmacists play a crucial role in this by checking for changes in symptoms during routine visits and assessing for possible drug interactions that might influence TD presentation. They also build rapport by noting personal details about patients’ lives, which helps foster trust and encourages open communication about symptoms and medication experiences. By blending structured exams with casual check-ins, pharmacists maintain continuous oversight of the patient’s condition. Even in outpatient pharmacies without an obvious clinical team, pharmacists act as a critical link in patient care by coordinating with prescribers and other providers to ensure that TD management is integrated and responsive to patient needs.
Patient education is another cornerstone of pharmacists’ contributions to managing TD. Many patients may not initially understand what TD is or why it developed, so pharmacists provide reassurance that TD is a recognized, treatable condition. They help patients focus on their therapeutic goals, emphasizing how medications like VMAT2 inhibitors can improve symptoms and quality of life over time. Clear communication about expected timelines for efficacy, common adverse effects such as dizziness or sleepiness, and the importance of adherence supports better treatment outcomes. Pharmacists also share accessible resources, like patient-friendly information from organizations such as National Alliance on Mental Illness, to empower patients and caregivers with reliable knowledge, ultimately enhancing engagement and long-term management.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
